)
Mark Tornetta
VP of Biologics Discovery,
Tavotek Biotherapeutics
Mark has over 30 years of pre-clinical R&D experience at SmithKline Beecham/GSK, Centocor/Janssen of J&J, and Tavotek Biotherapeutics. He implemented 5 phage display based platforms that have indirectly and directly generated biological candidates into IND stage and lately into the market. He was a key contributor to the initial engineering of the anti-IL5 antibody (Nucala) and a lead contributor to the generation of an anti-GPRC5d bi-specific antibody (Talvey). Currently, Mark leads the TavoSelect platform at Tavotek Biotherapeutics that generates sdAbs called VHOs. Tavotek is currently focused on solid tumors and unmet hematological cancers, whereas their latest asset in Phase 1 clinical trial, is a multi-specific biologic called TAVO412.